Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Barinow-Wojewodzki

P2.13-14 the Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy

Journal of Thoracic Oncology

English

Related publications

P2.13-23 Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC

Journal of Thoracic Oncology

English

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

Journal of Thoracic Oncology

English

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Journal of Thoracic Oncology

English

P2.01-32 Economic Evaluation of Diagnostic Platforms for T790M Detection in Post EGFR-TKI NSCLC in Brazil

Journal of Thoracic Oncology

English

P2.13-28 Comparison of ddPCR and NGS in Liquid Biopsy to Pathology Results in EGFR-Mutated NSCLC

Journal of Thoracic Oncology

English

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer

English

P2.03-016 Clinical Utility of Liquid Biopsy for Detecting EGFR T790M Mutation Is Very Limited

Journal of Thoracic Oncology

English

MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis

Journal of Thoracic Oncology

English

P2.13-26 Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated With First-Line TKI

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Barinow-Wojewodzki

P2.13-14 the Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy

Related publications

P2.13-23 Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

P2.01-32 Economic Evaluation of Diagnostic Platforms for T790M Detection in Post EGFR-TKI NSCLC in Brazil

P2.13-28 Comparison of ddPCR and NGS in Liquid Biopsy to Pathology Results in EGFR-Mutated NSCLC

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer

P2.03-016 Clinical Utility of Liquid Biopsy for Detecting EGFR T790M Mutation Is Very Limited

MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis

P2.13-26 Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated With First-Line TKI